Wegovy (Semaglutide) Patent Expiration, LOE Window & CMS Spending

Wegovy (Semaglutide) by Novo Nordisk: FDA Orange Book core substance LOE 2031-12-05 (last listed 2041-02-17), 0 AB generics, $1.54B 2024 CMS Part D & Medicaid spend, and $1,349 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovo Nordisk
FDA Application & PathwayN215256 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-12-05
Last Listed Patent or Exclusivity Date2041-02-17
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.54B
2024 Medicare Part D Spend$301.3M
2024 Medicaid Spend$1.24B
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($1,349 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.